Return to Intended Oncologic Treatment (RIOT) in Resected Gastric Cancer Patients
Postoperative chemotherapy (CMT) or chemoradiotherapy (CRT) is commonly recommended for gastric cancer (GC) patients in order to improve survival. However, some factors that prevent patients from return to intended oncologic treatment (RIOT) may increase the risk of recurrence and decrease the survival benefits achieved with curative resection. The aim of this study was to determine the frequency and factors associated with inability to RIOT and their impact on survival.
This retrospective study included stage II/III GC patients treated with potentially curative gastrectomy. Patients who could return to intended oncologic treatment (RIOT group) and those who could not (inability to RIOT group) were analyzed.
Of the 313 eligible GC patients, 89 (28.4%) and 85 (27.2%) patients receive CRT and CMT, respectively, representing a RIOT rate of 55.6%. The main reason was attributed to general poor performance status (30.2%), followed by surgical postoperative complications (POC) (20.1%). Older age, higher ASA, D1 lymphadenectomy, and major POC were related to inability to RIOT. Older age, neutrophil-lymphocyte ratio (NLR), and major POC were independent risk factors for inability to RIOT. Five-year DFS and OS were worse for the inability to RIOT group than for the RIOT group (p = 0.008 and p = 0.004, respectively). In multivariate analyses, absence of neoadjuvant therapy, total gastrectomy, pT3/T4, pN+, and inability to RIOT were associated with worse DFS. Type of gastrectomy, lymphadenectomy, pN status, Rx resection, and RIOT group were associated with OS.
Older age, high NLR, and major POC were risk factors for inability to RIOT. RIOT was an independent predictor of survival.
KeywordsGastric cancer Stomach neoplasms Chemotherapy postoperative complications Oncologic treatment
Marcus F.K.P. Ramos, Tiago B. de Castria, Marina A. Pereira: study design, data retrieval, statistical analysis, draft of the manuscript.
Andre R. Dias, Fernanda F Antonacio: data retrieval, review of the manuscript.
Bruno Zilberstein, Paulo M.G. Hoff, Ulysses Ribeiro Jr, Ivan Cecconello: critical analysis, review of the manuscript.
Compliance with Ethical Standards
The study was approved by the hospital ethics committee (NP993/16) and registered online (www.plataformabrasil.org.br). Informed consent of patients was waived because of the retrospective nature of the study.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 8.Tang L, Berlin J, Burgart L, et al. Protocol for the Examination of Specimens From Patients With Carcinoma of the Stomach. College of American Pathologists (CAP) 2014;220.127.116.11.Google Scholar
- 9.Ajani JA, In H, Sano T, et al. American Joint Committee on Cancer (AJCC). Cancer Staging Manual. 8th edition. Stomach. Springer 2017;17:203 - 220.Google Scholar
- 10.Doyle DJ, Garmon EH. American Society of Anesthesiologists Classification (ASA Class). StatPearls. Treasure Island FL: StatPearls Publishing LLC., 2017.Google Scholar
- 12.Szor DJ, Roncon Dias A, Pereira MA, et al. Neutrophil-lymphocyte ratio is associated with prognosis in patients who underwent potentially curative resection for gastric cancer. Journal of Surgical Oncology 2018.Google Scholar
- 16.Al-Batran S-E, Homann N, Schmalenberg H, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. Journal of Clinical Oncology 2017;35:4004-4004.CrossRefGoogle Scholar